Panel-negative strategy for suspected fusion-driven papillary thyroid carcinoma
Yoichiro Okubo, Ikki Takada, Mei Kadoya, Soji Toda, Shuka Wada, Katsuhiko Masudo, Yohei Miyagi, Hiroyuki Hayashi · 2026
Read Panel-negative strategy for suspected fusion-driven papillary thyroid carcinoma by Yoichiro Okubo, Ikki Takada, Mei Kadoya, Soji Toda, Shuka Wada, Katsuhiko Masudo, Yohei Miyagi, Hiroyuki Hayashi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13242143.txt.
Description
Okubo's team at Kanagawa Cancer Center warn thyroid pathologists against overreading a negative gene panel. Hotspot assays catch common mutations but can miss RET and NTRK fusions entirely. Morphology or clinical course may still scream fusion-driven cancer. Their correspondence sets out a panel-negative framework for exactly that gap.
Reports should state the assay's scope and any residual suspicion explicitly. Pan-TRK staining may triage cases but never rules fusions out. When suspicion persists and management hinges on it, RNA fusion testing should follow. The aim is killing false reassurance, not mandating more tests.
Catalog record
| CREATOR | Yoichiro Okubo, Ikki Takada, Mei Kadoya, Soji Toda, Shuka Wada, Katsuhiko Masudo, Yohei Miyagi, Hiroyuki Hayashi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |